Table 1.
Demographic and clinical characteristics
| Treatment (N = 23) |
Control (N = 39) |
P value | |
|---|---|---|---|
| Dialysis vintage (months) | 32.6 ± 24.2 | 41.3 ± 38.7 | 0.37 |
| Donor Age | 43.05 ± 15.69 | 50.89 ± 11.99 | 0.008 |
| Donor type (Living donor) | 9 (39.1%) | 12 (30.7%) | 0.5 |
| First kidney transplant | 13 (56.5%) | 27 (69.2%) | 0.31 |
| HLA mistmatch (A, B, DR) | 3.27 ± 1.1 | 3.8 ± 1.5 | 0.12 |
| Desensitization (PE + RTX) | 1 (4.34%) | 1 (2.56%) | 0.7 |
| Induction (Yes) | 16 (69.56%) | 30 (76.92%) | 0.52 |
| Thymoglobulin / ATG | 10 (43.48%) | 15 (38.46%) | 0.7 |
| Basiliximab | 3 (13.04%) | 13 (33.3%) | 0.8 |
| Other | 3 (13.04%) | 2 (5.12%) | 0.3 |
| IS at time of transplantation n (%) | |||
| Tacrolimus + MMF/MPA + PDN | 12 (52.2%) | 24 (58.9%) | |
| Cyclosporine + MMF/MPA + PDN | 3 (13.04%) | 5 (12.82%) | |
| Cyclosporine + PDN | 5 (21.74%) | 3 (7.69%) | |
| mTORi + MMF/MPA + PDN | 1 (4.35%) | 5 (12.82%) | |
| Tacrolimus + mTORi + PDN | 1 (4.35%) | 1 (2.56%) | |
| Cyclosporine + mTORi + PDN | 1 (2.56%) | ||
| Cyclosporine + Azathioprine + PDN | 1 (4.35%) | ||
| Previous treated rejections of this allograft | |||
| Cellular rejection | 6 (26.1%) | 10 (25%) | 0.97 |
| Humoral rejection | 7 (30.4%) | 6 (15.38%) | 0.26 |
| At the time of c-aABMR diagnosis | |||
| Sex (Female/Male) | 8/15 | 14/25 | 0.92 |
| Age (years) | 43.59 ± 13.2 | 53.6 ± 16.1 | 0.013 |
| Charlson comorbidity index (CCI) | 0.83 ± 1.1 | 0.97 ± 1.27 | 0.7 |
| Time KT to active c-aABMR (months) | 92.2 ± 75 | 93.3 ± 55.1 | 0.67 |
| eGFR (mL/min) at c-aABMR diagnosis | 30.9 ± 13.5 | 33.4 ± 11.6 | 0.45 |
| eGFR (mL/min) 6 months before cABMR | 40 ± 11 | 42.9 ± 10.2 | 0.3 |
| Proteinuria (mg/g) at c-aABMR diagnosis | 2286 ± 2248 | 1763 ± 1427 | 0.31 |
| DSA (+) | 6 /9 | 3 / 11 | 0.17 |
| Anti-HLA Antibodies (+) | 13 / 16 | 19 / 37 | 0.041 |
| IS at time of c-aABMR diagnosis n (%) | |||
| PDN + other IS | 17 (73.9%) | 22 (55%) | |
| Tacrolimus + MMF/MPA ± PDN | 9 (39.1%) | 17 (42.5%) | |
| mTORi + MMF/MPA ± PDN | 2 (8.69%) | 7 (17.5%) | |
| Cyclosporine + MMF/MPA ± PDN | 4 (17.39%) | 6 (15%) | |
| Tacrolimus + PDN | 3 (13.04%) | 4 (10%) | |
| MMF/MPA + PDN | 1 (4.34%) | 3 (7.5%) | |
| Cyclosporine ± PDN | 2 (8.69%) | 2 (5%) | |
| Tacrolimus + mTORi ± PDN | 1 (4.34%) | 1 (2.5%) | |
| Cyclosporine + mTORi | 1 (4.34%) | ||
Results are shown as mean ± SD or absolute frequencies (%) for quantitative and qualitative variables respectively. GFR glomerular filtrate rate, KT kidney transplant, IS immunossupression, mTORi mammalian target of rapamycin inhibitor, MMF/MPA mycophenolate mofetil or mycophenolic acid, cABMR chronic antibody-mediated rejection; PDN, prednisone, RTX Rituximab